Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 14-12-2008
  • E-pubdatum
  • 14-12-2008
  • Bron
  • Medische Oncologie

Panitumumab- en cetuximabmonotherapie in de derde lijn bij de behandeling van het chemotherapierefractair gemetastaseerd colorectaal carcinoom

Lees online Download PDF

Zowel panitumumab als cetuximab hebben als monotherapie therapeutische meerwaarde bij geselecteerde patiënten met een chemotherapieresistent gemetastaseerd colorectaalcarcinoom zonder aangetoonde KRAS-genmutatie.

Referenties 

  1. Saltz LB,Meropol NJ, Loehrer PJ sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
  2. Cunningham D,Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in ironotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
  3. Foon KA,Yang XD,Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984-90.
  4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signalling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8.
  5. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299-304.
  6. Roock W De, Piessevaux H, Schutter J De, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann of Oncol 2007; 19:508-5.
  7. Lievre A, Bachet JP, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
  8. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
  9. Karapetis C, Khambata-Ford S, Jonker D, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
  10. Cutsem E Van, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
  11. Amado RG,Wolf M, Freeman D, et al. Association of KRAS mutational status and efficacy of panitumumb monotherapy for the treatment (TX) of metastatic colorectal cancer (MCRC): results of pooled data from 4 clinical studies. Ann Oncol 2008;19(S):A359P.
  12. Cutsem E Van, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008;26(S):A2.
  13. Bokemeyer C, Bondarenko I, Hartmann J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008;26(S):A4000.
  14. Punt C, Tol J, Rodenburg C, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer: the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008;26(S):LBA4011.
  15. Jonker D, O’Callaghan C, Karapetis C, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 007;357:2040-8.
  16. Sobrero F, Maurel J, Fehrenbacher L, et al (EPIC). Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-9.
  17. Registratietekst uit European Public Assessment Report van de European Medicines Agency (www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-nl.pdf).
Lees meer